Jinyu Medical released the first social responsibility report of the third-party medical inspection industry, sharing medical technology progress with 20,000 medical institutions

According to the Arterial Network, recently, Guangzhou Jinyu Medical Testing Group Co., Ltd., the pioneer and leader of the domestic third-party medical testing industry, released its first corporate social responsibility report and was also the industry's first social responsibility report.

Golden Mile Medical Social Responsibility Report Release Ceremony

Since its inception, Jinyu Medical has established 37 medical laboratories, more than 2,000 logistics outlets, covering 90% of China's population, serving more than 20,000 medical institutions and providing about 2,500 testing projects.

The 80-page 2017 Social Responsibility Report officially disclosed the mission of Golden Mile Medicine to help health China. As a corporate citizen, Golden Mile Medicine, with its social strength, professional services and leading technologies, together with industry eco partners, promotes the equalization of basic medical and health services and helps the implementation of healthy China strategy.

Liang Yaoming, Chairman and CEO of Jinyu Medical, stressed: "Golden Field Medicine deeply understands the importance of corporate social responsibility, and starts with the third-party medical testing profession of enterprises, forming an organizational and institutionalized corporate social responsibility management model. And incorporate it into the organic components of corporate governance to power the sustainable and high-quality development of the company and the industry."

Establishing medical laboratories in 34 poverty-stricken counties across the country to promote equalization of basic medical care

"People's health is an important symbol of national prosperity and national prosperity." The report of the 19th National Congress of the Communist Party of China put forward the "Implementation of a Healthy China Strategy", "To improve the national health policy and provide all-round health services for the people." To this end, China is establishing a concept of great health and great health, and transforming the treatment of diseases into the center of people's health and continuously improving people's health and well-being.

Third-party medical testing is an important part of the socialization of medical and health services. It is a useful supplement to the existing medical resources in China. It provides a comprehensive medical examination and pathological diagnosis service to medical institutions at all levels to improve the level of clinical diagnosis and treatment. To improve the efficiency of the use of social medical resources. The report pointed out that Jinyu Medicine has always insisted on combining its own development with people's health and well-being, participating in the construction of healthy China, and promoting the equalization of basic medical and health services.

In 2017, Golden Mile Medicine actively strengthened the construction of regional center laboratories. Through the establishment of 37 medical laboratories, more than 2,000 logistics outlets, and the nation's first remote network of pathologists, Jinyu's service network has covered 90% of the country's population and more than 20,000 medical institutions. At the same time, Golden Mile will further extend and cover the service network to the county, community and community level, promote the further sinking of medical resources, and allow the nationals to enjoy quality medical resources. In 2017, Golden Mile cooperated with government or medical institutions in 38 localities to set up regional inspection and pathological diagnosis centers to provide international standard medical inspection technology and services for primary medical institutions. In addition, Golden Mile has set up cooperation and construction of medical laboratories in 34 poverty-stricken counties across the country to help improve the overall service level of regional and community medical care.

In response to the call for national policies, Golden Mile Medicine has also accelerated the distribution of service networks in remote areas of the west. In 2017, with the opening of Xinjiang Jinyu and Qinghai Jinyu, Jinyu has carried out medical inspection and pathological diagnosis outsourcing services in all western provinces, and achieved network coverage in most grassroots areas. Each year, Jinyu conducts academic exchanges and technical training for clinical, laboratory and pathological professionals in grassroots medical institutions. Nearly 30% of them come from grassroots medical institutions in western provinces and poverty-stricken areas, effectively enabling high-end medical testing and pathological diagnostic resources to benefit the grassroots. The people.

2,500 medical examination projects, sharing medical technology progress with Chinese people

Liang Yaoming said that participating in the implementation of the Healthy China Strategy and promoting the equalization of basic medical and health services is not only for the people at the grassroots level to seek medical treatment and to enjoy high-end scarce quality medical services, but also to share the advancement of medical technology with grassroots people. To this end, Jinyu Medical adheres to clinical and disease-oriented, professional pathological diagnosis and medical testing services and resource advantages to promote the improvement of precision medical care and effective management of national health, and unswervingly perform the latest technology and improve for Chinese patients. The mission of improving the level of care and improving the efficacy of patients is to protect the health of people's livelihood.

According to the report data, Jinyu Medical closely follows the international frontier, and continuously integrates multi-technology platforms around accurate diagnosis. It has developed and applied 2,500 medical detection and pathological diagnosis projects for patients, medical and health institutions, and the number is increasing year by year. Comprehensive clinical diagnostic support and full lifecycle diagnostic services.

Faced with a gap of up to 90,000 pathologists in China, Jinyu Medical established the nation's largest pathologist group consisting of more than 600 domestic and foreign pathologists, and led the establishment of the nation's first remote pathology collaboration network, in cooperation with regional medical institutions. 150 remote pathological ports provide pathological diagnosis services to more than 13,000 medical institutions across the country, solving the serious shortage of pathologists and realizing the sharing of pathologist resources.

At the same time, as a third-party medical inspection leader with an annual inspection sample of more than 50 million cases, Jinyu has accumulated a large amount of medical test data covering different ages, different regions, different ethnic groups, different groups of people, etc. Understand the epidemiology, help manage the health of the entire population, and even provide data support for precision medicine. Between 2016 and 2017, Jinyu Medical has published large data on diseases such as cervical lesions, renal pathology, vitamin D test, cervical cancer screening in rural women, and mass spectrometry detection of genetic metabolic diseases.

Annual investment of 256 million in research and development, leading the sustainable development of the industry

As a leader in the industry, Jinyu Medical has a mission to the sustainable development of the industry. It is committed to promoting the scientific and technological innovation of the medical inspection industry by introducing internationally advanced medical inspection technology, service concept, high-end discipline talents and independent innovation at home and abroad. Share advanced medical inspection techniques and knowledge with the industry.

The report reveals that because the domestic third-party medical inspection industry started late, it has become the main path of Jinyu medical innovation through independent innovation and introduction and digestion to absorb the mature experience and technology of European and American medical laboratories. Through this development path, Golden Field Medicine now has a full inspection diagnostic technology and corresponding technology platform covering the nucleic acid detection technology system, protein and metabolite detection technology system, and tissue, pathogenic microbial cell and subcellular morphology detection technology system.

By integrating various technology platforms, Jinyu Medical has also formed a number of clinical and disease-oriented laboratory comprehensive diagnostic centers, and built its own core technology system. In 2017, Jinyu R&D investment reached 259,873,700 yuan, accounting for 6.75% of operating income.

In order to enhance the ability of scientific research and innovation, in 2017, Jinyu Medical also established the Jinyu Medical Academic Committee, chaired by Academician Zhong Nanshan, and served by three academicians including Zeng Yizhen, Chen Runsheng and Hou Fanfan, and 23 domestic and overseas inspection, pathology, clinical, etc. The industry's top experts are dedicated to the in-depth exploration of research and development, clinical transformation, and industrialization of cutting-edge international technology, and vigorously promote the development and application of biological sample database construction, healthy big data development, artificial intelligence-assisted diagnosis, etc. Together to help the scientific and technological progress of the national medical testing industry.

The core driving force for innovation is talent. Jinyu has spared no effort to promote the cultivation of high-tech talents in the pathology and medical testing industry, which has brought lasting motivation to the development of the industry. Golden Mile academic conference held every year thousands of games at all levels, by building academic exchange platform for industry professionals the opportunity to increase technical exchanges, and promote medical workers continue to be re-educated so that nearly ten thousand medical institutions about 100,000 medical workers benefited .

Continue to practice public welfare responsibility and reduce government investment

In addition to incorporating corporate social responsibility into every detail in business development, Golden Mile Medicine has always continued to fulfill its public responsibilities in a professional spirit. The report pointed out that Jinyu adheres to the concept of healthy China, adheres to the concept of “professional public welfare”, and exerts its own technical and resource advantages, by supporting community health construction, medical poverty alleviation, community clinics, voluntary blood donation, and organizing various volunteer services. Actively participate in community building and carry forward great love.

Jinyu Medical cooperates with relevant communities and township health service organizations in various business areas to actively undertake free pre-pregnancy screening, women's “two cancer” screening programs, neonatal genetic metabolic disease testing, and chronic disease monitoring projects. For example, since 2009, it has participated in the National Rural Women's “Two Cancers” (Cervical Cancer and Breast Cancer) screening program. As of December 2017, it has completed the screening of cervical cancer screening specimens covering more than 19 provinces and more than 4 million people. Through the “community township service model”, Golden Mile Medicine continues to care for local children and women's health, greatly reducing the repeated investment in the construction of relevant communities and township medical institutions, reducing costs and reducing government investment.

Facing the future, Liang Yaoming said that Jinyu Medicine will continue to take "Dedication to Pursue Human Health, Harmony and Happiness" as its mission, and actively participate in and help the national medical reform and a series of health and welfare projects with a high degree of social responsibility. Healthy China, guarding the health of the people, and creating a model for the industry.